When supply chains become lifelines: A year to remember

This is the new reality of healthcare logistics. As pharmaceutical companies develop increasingly sophisticated biologics, specialty medicines, and cell and gene therapies, supply chains are becoming more critical – and more complex – than ever before. Meanwhile, aging populations are increasing demand for healthcare globally, while major patent expirations are reshaping pharmaceutical markets and creating new distribution requirements.

In life sciences and healthcare, supply chains do more than move products. They enable treatments, support surgeries, and ensure patients receive care when they need it. As therapies become more specialized and time-sensitive, the margin for error is shrinking. A delay isn’t just operational – it can directly affect patient outcomes.

At the same time, the environment these supply chains operate in is becoming less predictable. Geopolitical instability and disrupted trade routes are now structural realities.

“What used to be rare events are now daily challenges,” notes Oscar de Bok, CEO of DHL Global Forwarding. For years, the prevalent idea was to build supply chains mainly for efficiency, but the world is learning that such finely tuned networks often lack the flexibility to absorb shocks. “Today, the defining question isn’t how to avoid disruption entirely, but how quickly supply chains can respond and recover when disruption inevitably occurs.”

This shift is particularly pronounced in healthcare. Products are more sensitive, regulations more demanding, the consequences of failure immediate. A single temperature deviation can render a shipment unusable. A missing component can delay a critical procedure. 

The third pillar of LSHC growth is extending our long-term partnerships and business agreements with pharmaceutical and medtech companies, to expand integrated solutions. Among many others, two important examples from the past year include: vaccine distribution for Sanofi in France and a joint venture with BJC Group in Thailand.

Finally, we’ve gone big on advances in cold chain logistics, digital visibility and end-to-end platforms to improve how networks perform in real time. A key move here was a major investment in the DHL Airfreight Network, an expanded, dedicated pharma airfreight network that ensures fast, reliable temperature-controlled transport for critical products. Another effort to differentiate capabilities was the in-house creation of LifeTrack, a visibility application for LSH customers, which provides real time visibility and condition monitoring of shipments for parameters such as temperature, humidity, shock, ensuring that treatments reach patients in perfect condition.

Taken together, these efforts and more (see below) reflect the fundamental shift taking place across the Life Sciences & Healthcare sector. Advances in biopharma, personalized medicine, digital health, and new care models are redefining what customers expect from their supply chain partners.

Success will increasingly depend on specialised capabilities, integrated global networks, and digitally enabled solutions that can support the industry's evolving needs. Organizations investing in these capabilities today are helping define the future of healthcare logistics.